Journals Library

An error occurred retrieving content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

This trial showed that in patients with HER2-positive early breast cancer, 6 months' adjuvant trastuzumab was non-inferior to 12 months', with less cardiac toxicity and fewer severe adverse events.

{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron & Janet A Dunn.

Helena Earl 1,2,3,*, Louise Hiller 4, Anne-Laure Vallier 5, Shrushma Loi 4, Karen McAdam 6,7, Luke Hughes-Davies 1,7, Daniel Rea 8, Donna Howe 4, Kerry Raynes 4, Helen B Higgins 4, Maggie Wilcox 9, Chris Plummer 10,11, Betania Mahler-Araujo 12,13, Elena Provenzano 3,12, Anita Chhabra 14, Sophie Gasson 4, Claire Balmer 4, Jean E Abraham 1,2,3, Carlos Caldas 1,2,3,15, Peter Hall 16, Bethany Shinkins 17, Christopher McCabe 18, Claire Hulme 17,19, David Miles 20, Andrew M Wardley 21,22, David A Cameron 16, Janet A Dunn 4

1 Department of Oncology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
2 Cambridge Breast Cancer Research Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
3 NIHR Cambridge Biomedical Research Centre, Cambridge, UK
4 Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
5 Cambridge Clinical Trials Unit – Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
6 Department of Oncology, North West Anglia NHS Foundation Trust, Peterborough City Hospital, Peterborough, UK
7 Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
8 Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
9 Independent Cancer Patients’ Voice, London, UK
10 Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
11 Department of Cardiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
12 Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
13 Metabolic Research Laboratories, University of Cambridge, Cambridge, UK
14 Pharmacy, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, UK
15 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
16 Edinburgh University Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
17 Academic Unit of Health Economics, University of Leeds, Leeds, UK
18 Institute of Health Economics, Edmonton, AB, Canada
19 Health Economics Group, University of Exeter Medical School, Exeter, UK
20 Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK
21 NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
22 Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
* Corresponding author Email: hme22@cam.ac.uk

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

 

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 2 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions